Edesa Biotech, Inc.: 5%+ holders

As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Edesa Biotech, Inc. The largest reported stake is Pardeep Nijhawan's, at 16.31%. 16 filings are on record since February 13, 2026 (Schedule 13D/A, August 25, 2026).

Velan Capital Master Fund LP also filed stake reports on 2 other companies ↓

Sell to companies like Edesa Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-04 · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 1,172,617 · Sole dispositive: 0 · Shared dispositive: 1,172,617 · SCHEDULE 13G/A, 2026-11-04
• Filing 2026-08-26 · Reporting person: Stonepine Capital Management, LLC · Sole voting: 0 · Shared voting: 953,739 · Sole dispositive: 0 · Shared dispositive: 953,739 · SCHEDULE 13G, 2026-08-26
• Filing 2026-08-25 · Reporting person: Pardeep Nijhawan Medicine Professional Corporation · Sole voting: 0 · Shared voting: 1,164,676 · Sole dispositive: 0 · Shared dispositive: 1,164,676 · SCHEDULE 13D/A, 2026-08-25
• Filing 2026-08-25 · Reporting person: Velan Capital Master Fund LP · Sole voting: 0 · Shared voting: 1,081,385 · Sole dispositive: 0 · Shared dispositive: 1,081,385 · SCHEDULE 13D/A, 2026-08-25
• Filed 2026-06-18 · Holder: Integrated Core Strategies (US) LLC · Percent: 5.4% · SCHEDULE 13G

Edesa Biotech, Inc. has 16 Schedule 13D or 13G filings on record since 2026-02-13. 7 holders' latest filing reports 5% or more of common shares, without par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Edesa Biotech, Inc. and the warning signs.

See Edesa Biotech, Inc.'s free Snapshot Watch Edesa Biotech, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Edesa Biotech, Inc. and the records around it.

Edesa Biotech, Inc. elsewhere on the record

• Company profile and every filing Jun 2026
• Form D filing Jun 2026
• Who owns it

Companies that share a holder

• Velan Capital Master Fund LP also filed stake reports on 2 other companies: Jasper Therapeutics, Inc. (Aug 2026), InspireMD, Inc. (May 2026)
• Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), CalciMedica, Inc. (Aug 2026), AEON Biopharma, Inc. (Jul 2026)
• Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)

Want the whole picture on Edesa Biotech, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Edesa Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Edesa Biotech, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   18 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Edesa Biotech, Inc. by CUSIP 27966L306 and gives its principal executive office as 100 Spy Court, Markham (SCHEDULE 13G/A, 2026-11-04).

Source of funds (Item 3)

Item 3 is hereby supplemented as follows: Since the filing of the Schedule 13D/A on June 16, 2026, the Issuer has granted Dr. Pardeep Nijhawan the following restricted stock units, which vested in full upon grant: (i) 3,378 restricted share units on July 2, 2026 and (ii) 5,324 restricted share units on August 3, 2026. Such restricted share units were granted in lieu of partial salary.Pardeep Nijhawan, SCHEDULE 13D/A, 2026-08-25

Item 3 is hereby amended and restated to read as follows: The securities of the Issuer purchased by Velan Master, Velan Horizon and Velan Opportunity II were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). Pursuant to the Purchase Agreement (as defined in the initial Schedule 13D), Velan Master purchased 421,875 Shares and 366 Preferred Shares (as defined in the initial Schedule 13D) for $4,470,000.Velan Capital Investment Management LP, SCHEDULE 13D/A, 2026-08-25

Purpose of Transaction (Item 4)

Velan Capital Investment Management LP

Item 4 is hereby amended to add the following: On August 21, 2026, in an underwritten public offering (the "Offering"), Velan Master purchased 445,100 Shares and certain warrants (the "New Warrants") exercisable into 445,100 Shares and Velan Horizon purchased 9,445 Shares and New Warrants exercisable into 9,445 Shares. Velan Master and Velan Horizon may not exercise any portion of the New Warrants to the extent that they would beneficially own more than 9.99% of the number of Shares outstanding immediately after giving effect to such exercise. However, upon at least 61 days' prior notice to the Issuer, such Reporting Person may increase or decrease such beneficial ownership limitation, as applicable, but not to any percentage in excess of 9.99% (the "Warrant Ownership Limitation"). Each New Warrant is exercisable for one Share at an exercise price of $7.50 per Share. The New Warrants are exercisable at any time after their original issuance and may be exercised until the date that is the earlier of (i) the 18-month anniversary of the original issuance date and (ii) the 30th day following the date of the Issuer's public announcement of Phase 2 vitiligo topline data for EB06. The exercise price and the number of Shares issuable upon exercise of the New Warrants are subject to appropriate adjustment in the event of certain share dividends, share splits, share combinations or other similar reclassifications affecting the Shares. The foregoing description of the New Warrant is …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-25; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Edesa Biotech, Inc.

Who owns Edesa Biotech, Inc.?

On this page, 7 holders' latest ownership filings report 5% or more of Edesa Biotech, Inc.: Pardeep Nijhawan (16.31%, Schedule 13D/A, filed 2026-08-25), Velan Capital Investment Management LP (9.99%, Schedule 13D/A, filed 2026-08-25), Integrated Core Strategies (US) LLC (8.7%, Schedule 13G/A, filed 2026-11-04), Rubric Capital Management LP (7.74%, Schedule 13G, filed 2026-05-15) and Sirenia Capital Management LP (7.2%, Schedule 13G, filed 2026-05-15); 2 more are listed above.

Who are the largest shareholders of Edesa Biotech, Inc.?

By the share each holder's latest filing reports, the largest holders of Edesa Biotech, Inc. on this page are Pardeep Nijhawan (16.31%), Velan Capital Investment Management LP (9.99%) and Integrated Core Strategies (US) LLC (8.7%).

When did Pardeep Nijhawan buy into Edesa Biotech, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Pardeep Nijhawan on this page is the Schedule 13D/A, filed 2026-03-02, reporting 19.99%; its latest, Schedule 13D/A filed 2026-08-25, reports 16.31%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Edesa Biotech, Inc.

Swipe the table sideways to see every column.

Edesa Biotech, Inc.: every filing and event

Tools for this story

Each opens in a new tab, filled in for Edesa Biotech, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Edesa Biotech, Inc. is mentioned again
• Find former Edesa Biotech, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes